Navigation Links
Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
Date:11/6/2009

HAYWARD, Calif., Nov. 6 /PRNewswire/ -- Intarcia Therapeutics, Inc. delivered two presentations today on its ITCA 650 (DUROS® continuous delivery of exenatide) program for the treatment of type 2 diabetes at the Ninth Annual Diabetes Technology Meeting in San Francisco, CA:

(Logo: http://www.newscom.com/cgi-bin/prnh/20050301/SFTU126LOGO)

Continuous Subcutaneous Delivery of Exenatide Via ITCA 650 Lowers Plasma Glucose, HbA1c and Reduces Weight in a 28-day Phase 1b Study in Type 2 Diabetes, K. Luskey, J. McNally, J. Dahms, T. Alessi

Stability of ITCA 650 for Continuous Subcutaneous Delivery of Exenatide at Body Temperature for 12 Months, B. Yang, C. Negulescu, R. D'Vaz, C. Eftimie, J. Carr, S. Lautenbach, K. Horwege, R. Mercer, D. Ford, T. Alessi

Intarcia's ITCA 650 phase 1b clinical study was conducted at multiple centers in the United States and evaluated a 28-day course of ITCA 650 treatment among in patients with type 2 diabetes on a stable treatment regimen of diet and exercise or treatment with metformin and/or thiazolidinediones. The study included 4 dose arms (10-12 patients/dose arm) to which patients were randomized to receive 10 mcg/day, 20mcg/day, 40 mcg/day or 80 mcg/day of exenatide for a 28-day treatment duration. ITCA 650 therapy was administered for the full course of treatment with a single insertion of the ITCA 650 on day 1 and removal on day 29.

    Fasting & Postprandial Glucose  ITCA 650 Dose Arms (continuous daily dose)
                                    -----------------------------------------
                                      10          20          40         80
                                    mcg/day     mcg/day     mcg/day    mcg/day
                                 
'/>"/>
SOURCE Intarcia Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
2. Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
3. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
4. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
5. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
6. Cell Therapeutics, Inc.s (CTI) Presentation at BIO Investor Forum to be Webcast
7. Oxygen Biotherapeutics, Inc. Expands Board of Directors
8. The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
9. New Oxygen Biotherapeutics, Inc. Investor Presentation Available on Company Website
10. Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report
11. Sorrento Therapeutics, Inc. and QuikByte Software, Inc. Complete Merger

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... The New York investment bank KTA C...U) has agreed an AU$6.7 mil convertible note priva...he private placement was arranged by KTA Capital a... , New York (PRWEB) Novemb... bank KTA Capital, LLC ("KTA Capital") h...
(Date:11/24/2009)... Health care employment grew by 2...nly one to show consistent growth during the U.S. ...s remain in trouble, and health systems are coming...l, instead of just administrators. , ...re employment continued growing in October despite...
(Date:11/24/2009)...ATTLE,Nov.24/PRNewswire/--BlueMarbleEnergyCorp.ann...mentAuthority(OPDA)wererecentlyawarded$2millionbyW...rd(CERB)inaprivate/publicpartnershiptoconstructthe...lnCounty,WA. ,, "Thisinvestmentwillsignificantl...greenjobstoLincolnCounty,"saidBlueMarbleEnergyCEOK...
(Date:11/24/2009)...NDIEGO,Nov.24,2009/PRNewswire-FirstCall/--ArenaPha...atthecompanyisscheduledtopresentatthePiperJaffray2...30a.m.EasternTime(8:30a.m.PacificTime)attheNewYork...t andChiefExecutiveOfficer,isscheduledtoprovideano...tanddiscoveryprograms. ,, Aliveaudiowebcastofth...
Breaking Biology Technology:KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2
...able Patients in Phase I Study Receiving Combinati...ctive Tumor Response or Stable ...ts to Date in Ongoing Phase II Breast Cancer ...Disease -, CHICAGO and TUSTIN, Calif., June 2 Pe...ay announced that results from a,Phase I clinical ...
...RNewswire-FirstCall/ - Oncolytics Biotech Inc. (TS...ts of a Phase II study of,intravenous REOLYSIN(R) ...ere presented yesterday at the American Society of...entation, entitled "A Phase II Study of,Intravenou...f Patients with,Bone and Soft Tissue Sarcomas Meta...
... Safety and Preliminary Efficacy and Supports Furt...AC94, BOSTON and SEATTLE, May 30 Targeted Geneti...ase earlier today, entitled,"Targeted Genetics Rep...linical Trial," announcing additional interim data...atients with inflammatory arthritis. Pervin,Ankles...
Other Biology Technology:Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study 2Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study 3Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study 4Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study 5Oncolytics Biotech Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting 2Clarification on Press Release Issued Earlier Today: Targeted Genetics Confirms Positive, Interim Phase 1/2 Study Findings 2Clarification on Press Release Issued Earlier Today: Targeted Genetics Confirms Positive, Interim Phase 1/2 Study Findings 3
(Date:11/25/2009)...t Larisch, Head of the Cell Death Research Laborat...logy, has been awarded the prestigious Johnson & J...oring the cause of brain cell damage in Parkinson,...o scientists in support of innovation and excellen...ly conferred earlier this month at an event at the...
(Date:11/25/2009)...ourse of a lifetime, the heart pumps some 250 mill... to do this, the muscle fibers of the heart have t...by Dr. Wolfgang Rottbauer, vice chair of the Depar...pital (Chairman: Prof. Dr. H. A. Katus), has disco...ity of the smallest muscular unit, the sarcomere. ...
(Date:11/25/2009)..., CAWhen you eat may be just as vital to your heal...Institute for Biological Studies. Their experiment...g of thousands of genes in the liverthe body,s met...ntake and not by the body,s circadian clock as con...ermines the activity of a large number of genes co...
Breaking Biology News(10 mins):Johnson & Johnson award goes to research of the cause of brain cell damage in Parkinson's 2New genetic cause of cardiac failure discovered 2Feeding the clock 2Feeding the clock 3Novel DNA vaccine leads to kidney damage prevention in systemic lupus erythematosus models 48620 1Novel DNA vaccine leads to kidney damage prevention in systemic lupus erythematosus models 48620 2The BBVA Foundation presents its Frontiers of Knowledge Awards 8801 1The BBVA Foundation presents its Frontiers of Knowledge Awards 8801 2Nutricia launches Nutra Neocate weaning product designed for cows 26 23146 3B milk protein allergy 8798 1Nutricia launches Nutra Neocate weaning product designed for cows 26 23146 3B milk protein allergy 8798 2
...An atomic-resolution view of an enzyme found only ... of Washington (UW) clues about how this enzyme, e...phodiesterase 6 (PDE6), is central to the way ligh...of signals to the brain. , This particular form ...f the retina and has not been well-researched, in ...
...ning County Sheriff,s Office Replaces Passwords wi...ess to IT Systems, CHANHASSEN, Minn. and WALL, N....ational, Inc. (OTC Bulletin Board: BKYI), a leader...less public safety solutions,and its partner Sig-T...tware solutions, announced today the successful de...
...cientists have found lichens can give insight into...nd San Bernardino mountain ecosystems, and protect...ecies., Their findings are presented this month i...on and are significant because nitrogen from air ...al effects to terrestrial and aquatic ecosystems. ...
Other Biology News:Atomic-resolution views suggest function of enzyme that regulates light-detecting signals in eye 2Sig-Tec(R) and BIO-key(R) Deliver Advanced Biometric Security Solution to Ohio County Law Enforcement Agency 2Sig-Tec(R) and BIO-key(R) Deliver Advanced Biometric Security Solution to Ohio County Law Enforcement Agency 3Sig-Tec(R) and BIO-key(R) Deliver Advanced Biometric Security Solution to Ohio County Law Enforcement Agency 4Lichens function as indicators of nitrogen pollution in forests 2
...roducing our Regulatory Edition of Molecular Imagi...s for life science research and drug discovery app... compliance with U.S. Food and Drug Administration...ectronic Records; Electronic Signatures [21 CFR Pa...
...micon Select Tissue Arrays are intended for labora...re fixed in neutral buffered formalin and embedded... was performed by certified pathologists. Tissue ...relocated into a new recipient paraffin block, in ...
...ePix Pro is the industry standard microarray image...on of imaging and analysis tools, visualizations, ...se. GenePix Pro is included with every GenePix sca...arty scanners and all types of arrays. A wide rang...
... applications not requiring confocal, the BD Pathw...way 435. And, the Pathway 415 can be field-upgrade... High-performance, laser-based autofocus is standa...ra autofocus, or a combination of both. Robot-com...
Biology Products: